Products

  1. Home
  2. Products
  3. Bone & Mineral Metabolism
  4. IDKmonitor® Golimumab Drug Level ELISA K 9656

IDKmonitor® Golimumab Drug Level ELISA K 9656

$946.00

In Stock

Method: ELISA
Sample Type (Matrix): Serum, EDTA Plasma
Sample Volume: 10 µl
Species: Human
Incubation time: 2h 10m
Standard Range: 4.15-225 ng/ml
Size: 96 wells
Regulatory Status: Health Canada Licensed.
Kit Manual: Download

Tumor Necrosis Factor-alpha (TNFα) belongs to the proinflammatory cytokines, which promote and sustain inflammatory reactions. It is produced by macrophages and T cells and plays a central role in both acute and chronic inflammations. Consequently, chronic inflammatory diseases like Crohn’s disease, ulcerative colitis, rheumatoid arthritis, or psoriasis are increasingly being treated with antibodies against TNFa, which directly target the underlying inflammatory processes.

The clinical efficacy of an anti-TNFa therapy usually correlates with the trough level of the therapeutic antibody, meaning the drug level just before the next application of the anti-TNFa antibody. Several factors influence the trough level, among them dosage and frequency of anti-TNFa blocker infusion, disease activity, individual pharmacokinetics, and immune reaction (formation of anti-drug antibodies, ADA).

It is thought that ADA functionally neutralizes the therapeutic antibodies or induces their rapid elimination. Consequences of ADA formation can be therapy failure and allergic reactions during anti-TNFα antibody application.

The IDKmonitor® Golimumab Drug Level ELISA is intended for the quantitative determination of free golimumab (therapeutic antibody against TNFα, e.g. SIMPONI®) in EDTA plasma and serum.

The IDKmonitor® Golimumab Drug Level ELISA can help physicians monitor and optimize therapy early on.

Additional information

Weight35.5 oz
Dimensions6.5 × 10 × 4.5 in
Social media & sharing icons powered by UltimatelySocial

Become an IDK Insider!

Join our mailing list to receive the latest news and updates from Immundiagnostik, Inc.

 
 
 
 

You have Successfully Subscribed!